DJIA 18,058.49 20.52 0.11%
NASDAQ 5,056.48 -3.77 -0.07%
S&P 500 2,112.03 3.11 0.15%
market minute promo

15.98 0.20 (1.27%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

HALO $15.98 1.27%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $15.82
Previous Close $15.78
Daily Range $15.21 - $16.12
52-Week Range $6.88 - $17.27
Market Cap $2.0B
P/E Ratio -28.18
Dividend (Yield) $0.00 (0.0%)
Volume 578,539
Average Daily Volume 1,460,576
Current FY EPS -$0.45

Sector

Healthcare

Industry

Drug Makers

Halozyme Therapeutics, Inc. (HALO) Description

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets. Website: http://www.halozyme.com/

News & Commentary Rss Feed

Can Pfizer’s Cholesterol Drug Catch Up To The Competition?

Pfizer’s bococizumab remains in last place in the PCSK9 race. Will it arrive too late to make a meaningful impact on the market?

2 Small Biotech Stocks In Full Breakout Mode

Two Small Biotech Stocks In Full Breakout Mode

Halozyme Issues New Preclinical Data at ASCO: PEGPH20 Boosted T-Cell Access to Tumor Cells in Animal

Halozyme Issues New Preclinical Data at ASCO: PEGPH20 Boosted T-Cell Access to Tumor Cells in Animals

Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog

MLV: We're Reiterating A Buy On Halozyme

Halozyme Therapeutics Spikes Up Following FDA News

Individual Investor Portfolio: Select Sectors And Companies Continue To Beat Market Indices And Peer

Individual Investor Portfolio: Select Sectors And Companies Continue To Beat Market Indices And Peer Groups

Commit To Buy Halozyme Therapeutics At $10, Earn 15.5% Using Options

Insider Trading Alert - GCAP, HALO And ALIM Traded By Insiders

Halozyme Q4 Loss Narrower-than-Expected, Revenues Up - Analyst Blog

See More HALO News...

HALO's Top Competitors

HALO $15.98 (1.27%)
Current stock: HALO
AMGN $163.41 (0.63%)
Current stock: AMGN
GILD $102.83 (-0.11%)
Current stock: GILD
BIIB $384.81 (-1.15%)
Current stock: BIIB